{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:19:59Z","timestamp":1785881999830,"version":"3.56.0"},"posted":{"date-parts":[[2020,12,11]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":33,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2020,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Airline travel has been significantly reduced during the COVID-19 pandemic due to concern for individual risk of SARS-CoV-2 infection and population-level transmission risk from importation. Routine viral testing strategies for COVID-19 may facilitate safe airline travel through reduction of individual and\/or population-level risk, although the effectiveness and optimal design of these \u201ctest-and-travel\u201d strategies remain unclear.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We developed a microsimulation of SARS-CoV-2 transmission in a cohort of airline travelers to evaluate the effectiveness of various testing strategies to reduce individual risk of infection and population-level risk of transmission. We evaluated five testing strategies in asymptomatic passengers: i) anterior nasal polymerase chain reaction (PCR) within 3 days of departure; ii) PCR within 3 days of departure and PCR 5 days after arrival; iii) rapid antigen test on the day of travel (assuming 90% of the sensitivity of PCR during active infection); iv) rapid antigen test on the day of travel and PCR 5 days after arrival; and v) PCR within 3 days of arrival alone. The travel period was defined as three days prior to the day of travel and two weeks following the day of travel, and we assumed passengers followed guidance on mask wearing during this period. The primary study outcome was cumulative number of infectious days in the cohort over the travel period (population-level transmission risk); the secondary outcome was the proportion of infectious persons detected on the day of travel (individual-level risk of infection). Sensitivity analyses were conducted.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>Assuming a community SARS-CoV-2 incidence of 50 daily infections, we estimated that in a cohort of 100,000 airline travelers followed over the travel period, there would be a total of 2,796 (95% UI: 2,031, 4,336) infectious days with 229 (95% UI: 170, 336) actively infectious passengers on the day of travel. The pre-travel PCR test (within 3 days prior to departure) reduced the number of infectious days by 35% (95% UI: 27, 42) and identified 88% (95% UI: 76, 94) of the actively infectious travelers on the day of flight; the addition of PCR 5 days after arrival reduced the number of infectious days by 79% (95% UI: 71, 84). The rapid antigen test on the day of travel reduced the number of infectious days by 32% (95% UI: 25, 39) and identified 87% (95% UI: 81, 92) of the actively infectious travelers; the addition of PCR 5 days after arrival reduced the number of infectious days by 70% (95% UI: 65, 75). The post-travel PCR test alone (within 3 days of landing) reduced the number of infectious days by 42% (95% UI: 31, 51). The ratio of true positives to false positives varied with the incidence of infection. The overall study conclusions were robust in sensitivity analysis.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>Routine asymptomatic testing for COVID-19 prior to travel can be an effective strategy to reduce individual risk of COVID-19 infection during travel, although post-travel testing with abbreviated quarantine is likely needed to reduce population-level transmission due to importation of infection when traveling from a high to low incidence setting.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2020.12.08.20246132","type":"posted-content","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T14:13:01Z","timestamp":1607695981000},"source":"Crossref","is-referenced-by-count":6,"title":["Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation analysis"],"prefix":"10.64898","author":[{"given":"Mathew V","family":"Kiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth T","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Q","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd A C","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rodr\u00edguez-Barraquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Greenhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Bibbins-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Havlir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2020121211501266000_2020.12.08.20246132v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2002387"},{"key":"2020121211501266000_2020.12.08.20246132v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"2020121211501266000_2020.12.08.20246132v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31142-9"},{"key":"2020121211501266000_2020.12.08.20246132v1.4","doi-asserted-by":"crossref","unstructured":"Lewnard JA , Lo NC . Scientific and ethical basis for social-distancing interventions against COVID-19. Lancet Infect Dis 2020.","DOI":"10.1016\/S1473-3099(20)30190-0"},{"issue":"7820","key":"2020121211501266000_2020.12.08.20246132v1.5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41586-020-2404-8","article-title":"The effect of large-scale anti-contagion policies on the COVID-19 pandemic","volume":"584","year":"2020","journal-title":"Nature"},{"key":"2020121211501266000_2020.12.08.20246132v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30647-2"},{"issue":"11","key":"2020121211501266000_2020.12.08.20246132v1.7","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.3201\/eid2611.203254","article-title":"In-Flight Transmission of SARS-CoV-2","volume":"26","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2020121211501266000_2020.12.08.20246132v1.8","unstructured":"TSA. TSA checkpoint travel numbers for 2020 and 2019: https:\/\/www.tsa.gov\/coronavirus\/passenger-throughput?page=1 accessed 12\/1\/20, 2020."},{"key":"2020121211501266000_2020.12.08.20246132v1.9","first-page":"489","article-title":"Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)","volume":"368","year":"6490","journal-title":"Science 2020"},{"key":"2020121211501266000_2020.12.08.20246132v1.10","unstructured":"United Airlines Becomes First U.S. Carrier to Make COVID-19 Tests Available to Customers. 2020. https:\/\/hub.united.com\/2020-09-24-united-airlines-becomes-first-u-s-carrier-to-make-covid-19-tests-available-to-customers-2647787602.html."},{"key":"2020121211501266000_2020.12.08.20246132v1.11","unstructured":"Hawaii: Coronavirus (COVID-19) transportation related information and resources: https:\/\/hidot.hawaii.gov\/coronavirus\/. 2020 (accessed 11\/6\/20."},{"key":"2020121211501266000_2020.12.08.20246132v1.12","unstructured":"CDC. Testing and International Air Travel https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/travelers\/testing-air-travel.html accessed 12\/1\/20, 2020."},{"key":"2020121211501266000_2020.12.08.20246132v1.13","doi-asserted-by":"crossref","unstructured":"Chin ET , Huynh BQ , Chapman LAC , Murrill M , Basu B , Lo NC . Frequency of routine testing for COVID-19 in high-risk healthcare environments to reduce outbreaks. Clin Infect Dis 2020.","DOI":"10.1101\/2020.04.30.20087015"},{"issue":"5","key":"2020121211501266000_2020.12.08.20246132v1.14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"2020121211501266000_2020.12.08.20246132v1.15","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.3201\/eid2611.203299","article-title":"Transmission of SARS-CoV 2 During Long-Haul Flight","volume":"26","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"19","key":"2020121211501266000_2020.12.08.20246132v1.16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.15585\/mmwr.mm6919e4","article-title":"Identification and Monitoring of International Travelers During the Initial Phase of an Outbreak of COVID-19 - California, February 3-March 17, 2020","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020121211501266000_2020.12.08.20246132v1.17","unstructured":"CDC COVID Data Tracker: https:\/\/covid.cdc.gov\/covid-data-tracker\/#cases_casesper100klast7days 2020 (accessed 11\/10\/20."},{"key":"2020121211501266000_2020.12.08.20246132v1.18","doi-asserted-by":"crossref","unstructured":"Oran DP , Topol EJ . Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med 2020.","DOI":"10.7326\/M20-3012"},{"key":"2020121211501266000_2020.12.08.20246132v1.19","doi-asserted-by":"crossref","unstructured":"Sun K , Wang W , Gao L , et al. Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. Science 2020.","DOI":"10.1101\/2020.08.09.20171132"},{"key":"2020121211501266000_2020.12.08.20246132v1.20","doi-asserted-by":"crossref","unstructured":"Bajema KL , Wiegand RE , Cuffe K , et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Intern Med 2020.","DOI":"10.1001\/jamainternmed.2020.7976"},{"key":"2020121211501266000_2020.12.08.20246132v1.21","unstructured":"Kiang MV . GiHub Repository: github.com\/mkiang\/airline_testing_strategies. 2020."},{"key":"2020121211501266000_2020.12.08.20246132v1.22","unstructured":"CDC. Testing and International Air Travel: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/travelers\/testing-air-travel.html. accessed 11\/27\/20., 2020."},{"key":"2020121211501266000_2020.12.08.20246132v1.23","doi-asserted-by":"crossref","unstructured":"Kucirka LM , Lauer SA , Laeyendecker O , Boon D , Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med 2020.","DOI":"10.7326\/M20-1495"},{"key":"2020121211501266000_2020.12.08.20246132v1.24","doi-asserted-by":"crossref","unstructured":"Hay AH , Kennedy-Shaffer L , Kanjilal S , Lipsitch M , Mina M. Estimating epidemiologic dynamics from single cross-sectional viral load distributions. Pre-Print 2020.","DOI":"10.1101\/2020.10.08.20204222"},{"key":"2020121211501266000_2020.12.08.20246132v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30121-X"},{"key":"2020121211501266000_2020.12.08.20246132v1.26","doi-asserted-by":"crossref","unstructured":"Albert E , Torres I , Bueno F , et al. Field evaluation of a rapid antigen test (Panbio\u2122 COVID-19 Ag Rapid Test Device) for the diagnosis of COVID-19 in primary healthcare centers. Pre-Print 2020.","DOI":"10.1101\/2020.10.16.20213850"},{"key":"2020121211501266000_2020.12.08.20246132v1.27","doi-asserted-by":"crossref","unstructured":"Pilarowski G , Lebel P , Sunshine S , et al. Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco. Pre-Print 2020.","DOI":"10.1101\/2020.11.02.20223891"},{"key":"2020121211501266000_2020.12.08.20246132v1.28","doi-asserted-by":"crossref","unstructured":"Schwob JM , Miauton A , Petrovic D , et al. Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial: https:\/\/www.medrxiv.org\/content\/10.1101\/2020.11.23.20237057v1.full.pdf. 2020.","DOI":"10.1101\/2020.11.23.20237057"},{"key":"2020121211501266000_2020.12.08.20246132v1.29","doi-asserted-by":"crossref","unstructured":"Grassly NC , Pons-Salort M , Parker EPK , White PJ , Ferguson NM , Imperial College C-RT. Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study. Lancet Infect Dis 2020.","DOI":"10.1016\/S1473-3099(20)30630-7"},{"issue":"7","key":"2020121211501266000_2020.12.08.20246132v1.30","doi-asserted-by":"crossref","first-page":"e2016818","DOI":"10.1001\/jamanetworkopen.2020.16818","article-title":"Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States","volume":"3","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2020121211501266000_2020.12.08.20246132v1.31","doi-asserted-by":"crossref","unstructured":"Larremore DB , Wilder B , Lester E , et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv 2020.","DOI":"10.1101\/2020.06.22.20136309"},{"key":"2020121211501266000_2020.12.08.20246132v1.32","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0504"},{"key":"2020121211501266000_2020.12.08.20246132v1.33","doi-asserted-by":"crossref","unstructured":"Dickens BL , Koo JR , Lim JT , et al. Strategies at points of entry to reduce importation risk of COVID-19 cases and re-open travel. J Travel Med 2020.","DOI":"10.1093\/jtm\/taaa141"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2020.12.08.20246132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:01:05Z","timestamp":1768485665000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.12.08.20246132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1101\/2020.12.08.20246132","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/s1473-3099(21)00134-1","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2020,12,11]]},"subtype":"preprint"}}